MX2020010949A - Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas. - Google Patents

Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.

Info

Publication number
MX2020010949A
MX2020010949A MX2020010949A MX2020010949A MX2020010949A MX 2020010949 A MX2020010949 A MX 2020010949A MX 2020010949 A MX2020010949 A MX 2020010949A MX 2020010949 A MX2020010949 A MX 2020010949A MX 2020010949 A MX2020010949 A MX 2020010949A
Authority
MX
Mexico
Prior art keywords
prophylaxis
derivatives
novel
treatment
compounds
Prior art date
Application number
MX2020010949A
Other languages
English (en)
Inventor
Chungen Liang
Hongying Yun
Xiufang Zheng
Jianping Wang
Kun Miao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020010949A publication Critical patent/MX2020010949A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I), (ver Fórmula), en la que R1, R2 y R3 son como se han descrito en el presente documento, y sus profármacos o sales, enantiómeros o diastereómeros farmacéuticamente aceptables de los mismos, y composiciones que incluyen los compuestos y métodos para usar los compuestos.
MX2020010949A 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas. MX2020010949A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
MX2020010949A true MX2020010949A (es) 2022-06-16

Family

ID=55910966

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014033A MX2017014033A (es) 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.
MX2020010949A MX2020010949A (es) 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017014033A MX2017014033A (es) 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.

Country Status (33)

Country Link
US (3) US9708325B2 (es)
EP (1) EP3294740B1 (es)
JP (1) JP6738352B2 (es)
KR (1) KR102690131B1 (es)
CN (1) CN107580596B (es)
AR (1) AR104528A1 (es)
AU (3) AU2016260683B2 (es)
BR (1) BR112017023959B1 (es)
CA (1) CA2982704C (es)
CL (1) CL2017002745A1 (es)
CO (1) CO2017009994A2 (es)
CR (1) CR20170496A (es)
DK (1) DK3294740T3 (es)
ES (1) ES2753777T3 (es)
HK (1) HK1247925A1 (es)
HR (1) HRP20191942T1 (es)
HU (1) HUE045906T2 (es)
IL (2) IL254947B (es)
LT (1) LT3294740T (es)
MX (2) MX2017014033A (es)
MY (1) MY182353A (es)
NZ (1) NZ735648A (es)
PE (1) PE20171620A1 (es)
PH (1) PH12017502009A1 (es)
PL (1) PL3294740T3 (es)
PT (1) PT3294740T (es)
RS (1) RS59435B1 (es)
RU (1) RU2745269C2 (es)
SG (1) SG10202108841YA (es)
SI (1) SI3294740T1 (es)
TW (2) TWI706954B (es)
UA (1) UA120450C2 (es)
WO (1) WO2016180695A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120450C2 (uk) 2015-05-08 2019-12-10 Ф. Хоффманн-Ля Рош Аг Сполуки і похідні сульфонімідоїлпуринону для лікування і профілактики вірусної інфекції
SI3504210T1 (sl) * 2016-08-29 2021-08-31 F. Hoffmann-La Roche Ag 7-substituirane sulfonimidoilpurinonske spojine za zdravljenje virusne okužbe in zaščito pred njo
EP3970750A1 (en) * 2016-09-13 2022-03-23 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
EP3752505B1 (en) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
RU2020131012A (ru) * 2018-02-28 2022-03-28 Ф. Хоффманн-Ля Рош Аг 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
MX2021009644A (es) * 2019-02-12 2021-09-08 Ambrx Inc Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr.
EP4031544B1 (en) 2019-09-20 2024-02-28 Syngenta Crop Protection AG Pesticidally active heterocyclic derivatives with sulfur and sulfoximine containing substituents
WO2024013205A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
AU2006242920A1 (en) * 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
EA021377B9 (ru) * 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
IN2014MN00862A (es) 2011-11-09 2015-04-17 Janssen R & D Ireland
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
EA032824B1 (ru) 2014-08-15 2019-07-31 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
UA120450C2 (uk) * 2015-05-08 2019-12-10 Ф. Хоффманн-Ля Рош Аг Сполуки і похідні сульфонімідоїлпуринону для лікування і профілактики вірусної інфекції
SI3504210T1 (sl) * 2016-08-29 2021-08-31 F. Hoffmann-La Roche Ag 7-substituirane sulfonimidoilpurinonske spojine za zdravljenje virusne okužbe in zaščito pred njo

Also Published As

Publication number Publication date
US9708325B2 (en) 2017-07-18
AU2016260683B2 (en) 2020-10-29
CL2017002745A1 (es) 2018-05-18
US20200109144A1 (en) 2020-04-09
MY182353A (en) 2021-01-20
HK1247925A1 (zh) 2018-10-05
AU2016260683A1 (en) 2017-10-12
CA2982704A1 (en) 2016-11-17
HRP20191942T1 (hr) 2020-01-10
RU2017142577A (ru) 2019-06-10
IL254947B (en) 2021-02-28
ES2753777T3 (es) 2020-04-14
PT3294740T (pt) 2019-10-29
CR20170496A (es) 2017-12-05
NZ735648A (en) 2023-06-30
CO2017009994A2 (es) 2018-02-20
IL280769A (en) 2021-04-29
JP2018515509A (ja) 2018-06-14
IL280769B2 (en) 2023-07-01
JP6738352B2 (ja) 2020-08-12
CA2982704C (en) 2023-10-24
LT3294740T (lt) 2019-11-25
SI3294740T1 (sl) 2019-12-31
PE20171620A1 (es) 2017-11-02
AU2020256348A1 (en) 2020-11-12
AU2022204666A1 (en) 2022-07-21
US10399983B2 (en) 2019-09-03
BR112017023959A2 (pt) 2018-07-17
HUE045906T2 (hu) 2020-01-28
BR112017023959B1 (pt) 2023-05-02
DK3294740T3 (da) 2019-11-04
WO2016180695A1 (en) 2016-11-17
EP3294740B1 (en) 2019-09-04
RS59435B1 (sr) 2019-11-29
AR104528A1 (es) 2017-07-26
PH12017502009A1 (en) 2018-03-26
TW201716410A (zh) 2017-05-16
RU2017142577A3 (es) 2019-10-31
PL3294740T3 (pl) 2020-03-31
US11242345B2 (en) 2022-02-08
US20160326177A1 (en) 2016-11-10
UA120450C2 (uk) 2019-12-10
KR102690131B1 (ko) 2024-07-31
IL254947A0 (en) 2017-12-31
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
US20170275286A1 (en) 2017-09-28
TWI706954B (zh) 2020-10-11
MX2017014033A (es) 2018-03-01
CN107580596A (zh) 2018-01-12
KR20180003612A (ko) 2018-01-09
EP3294740A1 (en) 2018-03-21
AU2020256348B2 (en) 2022-06-16
SG10202108841YA (en) 2021-09-29
IL280769B1 (en) 2023-03-01
TWI768467B (zh) 2022-06-21
CN107580596B (zh) 2020-07-14

Similar Documents

Publication Publication Date Title
MX2021006902A (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.
PH12017501061B1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12017501258B1 (en) Pyrazine compounds for the treatment of infectious diseases
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MX2023001876A (es) Derivados de rapamicina.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2016014728A (es) Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
NZ746825A (en) Oxysterols and methods of use thereof
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
TN2017000031A1 (en) Imidazopyridazine compounds
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MX2022005912A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria.